Antisense oligonucleotides (ASOs) are short, synthetic 15–25 nt oligonucleotides that localize to the nucleus used to inhibit gene expression. Order Now!
Antisense oligonucleotides (ASOs) are short single stranded synthetic RNA or DNA molecules, whereas double-stranded RNA nucleotide sequences are called small interfering RNA (siRNA). ASOs bind to complementary nucleic acid sequences impacting the associated functions of the targeted nucleic a...
Antisense oligonucleotides (ASOs) were first discovered to influence RNA processing and modulate protein expression over two decades ago; however, progress translating these agents into the clinic has been hampered by inadequate target engagement, insufficient biological activity, and off-target toxic effec...
Antisense oligonucleotides, or ASOs, are 15–22 nt DNA sequences designed to bind complementary RNA targets, ultimately facilitating their degradation. ASO technology provided the first oligonucleotide-based approach to disrupting gene expression and has been used in knockdown experiments, target validation...
开发中的ASOs都是通过RNase H1或Argonaute 2(Ago 2)来促进RNA切割的。 RNase H1是一种内源性核酸酶,存在于大多数细胞中,它促进RNA-DNA异源双链中RNA的断裂。在哺乳动物细胞中,RNase H1存在于细胞核、线粒体和细胞质中,它具有多种功能,包括清除Okazaki片段中的RNA、DNA修复和R环的分解。被设计为利用RNaseH1...
反义寡核苷酸(ASOs)被定义为化学合成的寡核苷酸,通常长度为12-30个核苷酸,目的是通过Watson-crick碱基配对规则与RNA结合。 ASOs的长度部分地提高了它们的特异性,因为16到20个核苷酸长的寡核苷酸能够唯一地与一个目标RNA结合。在与靶向RNA结合后,...
Antisense oligonucleotides (ASOs) have been widely investigated as a potential drugs because of their ability to bind with the target DNA or RNA strands, which may lead to inhibition of translational processes. This review presents currently approved oligonucleotide (OGN) drugs and summarizes their ...
Introduction Antisense oligonucleotides (ASOs) represent a class of drugs which can be rationally designed to complement the coding or non-coding regions of target RNA transcripts. They could modulate pre-messenger RNA splicing, induce mRNA knockdown or block translation of disease-causing genes, ...
In a study published in the journalActa Neuropathologica Communicationson May 14, 2024, a research team from Tokyo Medical and Dental University (TMDU) explored the use of antisense oligonucleotides (ASOs) to reduce the expression of aSyn and improve symptoms in a mouse model of PD. ...
antisense oligonucleotidesThe invention relates to antisense oligonucleotides (ASOs), especially for use in producing truncated proteins, particularly a truncated version of APOB100. The ASOs can be used in therapy, particularly in the treatment of high cholesterol and related conditions....